Where Business Meets Science

Biopharma comprises 25% of the total pharma market and revenues have gone up by over 6000% from the 1990s to now. What are companies doing to keep up with this growth and innovation? Read this article to find out. 

How is biopharma striking a balance between modernizing drug development & delivery and the effort to rein in R&D expenses? While change is unlikely to be quick, there is consensus that pharma does need to embrace changes in drug development and delivery fully explore the wide range of opportunities that exist. 

Pipeline diversification, emerging therapies and shifting customer demands are the real dynamics reshaping the contract manufacturing market, according to experts. Almost every article written about contracting reports that demand for outsourced manufacturing services is growing and states that the CDMO sector is consolidating.

What role does empathy play in building successful teams, and in turn, businesses? Read on to find out how empathetic leadership promotes a strong corporate culture, and lays a strong foundation for success. 

The utilisation of artificial intelligence (AI) by the pharmaceutical industry is gathering pace rapidly. The technology has evolved beyond simple neural networks and machine learning towards a deep learning approach geared at producing insights which should in theory enable better business decision making.

The new decade has rolled in, bringing new and unprecedented challenges. New products with shorter lifecycles, aging population and rigorous regulatory scrutiny will play a role in shaping the industry. In this article, leading industry experts in the region share their views on what the most important trends will be for this year, and this decade

FDA approval of GW Pharmaceuticals’ Epidiolex® is widely considered to be a landmark in cannabinoid-derived drug development. Not only is Epidiolex® the first FDA-approved drug that contains a purified drug substance (cannabidiol) derived from the Cannabis sativa plant (marijuana), but it is also the first FDA approved drug for the treatment of patients with a rare and severe form of childhood epilepsy, Dravet syndrome.